OncLive News Network

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, explore the advantages of biomarker testing and next-generation sequencing in diagnosing and managing non-small cell lung cancer.

D. Ross Camidge, MD, PhD,of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses research efforts for patients with non–small cell lung cancer who harbor NRG1 fusions.

Christian Marth, MD, PhD, discusses implications of the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

Nikhil I. Khushalani, MD, discusses the diagnosis, outcomes, treatment landscape, and future directions of locally advanced or metastatic cutaneous squamous cell carcinoma.

Experts explore the clinical significance and practical implications of recent findings regarding a CAR T-cell therapy in real-world settings.

Two experts discuss the recent data presented at ASH 2023 on BCMA-targeted CAR-T therapies in relapsed/ refractory multiple myeloma patients.

Cathy Eng, M, FACP, FASCO presents a comprehensive End-of-Year Review in Colorectal Cancer (CRC), delving into the exploration of emerging treatment options and clinical insights on the future landscape. This insightful review includes a focus on the recent approval of fruquintinib and important updates on target therapies for HER2+, BRAF V600E-Mutant, and KRAS-mutant CRC, as well as an interactive Q&A segment.

Catherine Lai, MD, MPH, discusses strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), particularly for patients in first remission without a transplant. She also shares perspectives on updates from the 65th ASH Annual Meeting.

Richard Furman, MD, and Chaitra S. Ujjani, MD, discuss the changing landscape of treatment strategies for patients with CLL, highlighting key updates presented at ASH 2023 and their potential implication on clinical practice.

Experts provides an in-depth review of current and emerging options for the treatment of HR+, HER2- metastatic breast cancer, including discussions around overcoming endocrine resistance, sequencing combination therapies, and optimizing quality of life and outcomes.

Expert oncologist discuss key data from 2023 on the detection and treatment of prostate cancer.

Anwaar Saeed, MD, and Amit Singal, MD, explore recent updates in the treatment of advanced hepatocellular carcinoma (HCC) presented at the 2023 AASLD: The Liver Meeting Congress and surrounding meetings.

Brian Rini, MD, and Hans Hammers, MD, explore key data updates in the management of advanced renal cell carcinoma (RCC) presented at the 2023 IKCS: North America Congress and other recent meetings.

Join us LIVE at this year's 2023 ASH Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in hematologic malignancies, including chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic/myeloproliferative neoplasms, Hodgkin and non–Hodgkin lymphoma, multiple myeloma, and graft-vs-host-disease. The experts will share their insights and reactions to the pivotal data presented during the conference.

Floor J. Backes, MD, and Matthew Powell, MD, explore key data updates in the management of advanced or recurrent endometrial cancer presented at the 2023 ESMO Congress and other recent meetings.

Join us LIVE at this year's 2023 ESMO Congress! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Expert perspectives on the current diagnostic and treatment landscape for patients with low-grade serous ovarian cancer and how recent learnings have impacted real-world practice.

Joseph Gligorov, MD, reviews advancements in the treatment of HER2-positive breast cancer, including the pivotal DESTINY-Breast03 study, global perspectives, sequencing strategies based on French real-world evidence, and the management of adverse events in advanced therapies.

Giselle Sholler, MD, and Anurag Agrawal, MD, discuss the changing landscape of treatment strategies for patients with high-risk neuroblastoma and review key clinical trial data presented at the ASCO 2023 Annual Meeting.

Jae Park, MD, reviews key data in the management of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) recently presented at the ASCO 2023 Annual Meeting.

Preet M. Chaudhary, MD, PhD and Noah Merin, MD, PhD discuss the chronic graft versus host disease treatment landscape, covering first- and second-line treatments and emergent trial data.

Following the 2023 ASCO Annual Meeting, Tanios S. Bekaii-Saab, MD, discusses recent data updates and provides clinical insights on the evolving treatment landscape for metastatic colorectal cancer.

Megan Kruse, MD, reviews updates from the 2023 ASCO Annual Meeting and offers insights onthe evolving treatment landscape for HER2+ metastatic breast cancer.

Updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023.

Brian T. Hill MD, PhD, and Paulo Ghia, MD engage with recent data focusing on BTKis in CLL presented at the ICML 2023 Annual Meeting as well as how that data may be applied to clinical practice.

Join us LIVE at this year's 2023 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, gynecologic malignancies, melanoma, and sarcoma. The experts will share their insights and reactions to the pivotal data presented during the conference.

Tanios S. Bekaii-Saab, MD, FACP describes the current colorectal cancer (CRC) treatment landscape, shares relevant updates from the American Society for Clinical Oncology’s Gastrointestinal Cancers Symposium 2023, and discusses his hopes for the future of the field.